EMPA-HEART Cardiolink-6 Trial: A Randomized Trial Evaluating the Effect of Empagliflozin on Left Ventricular Structure, Function and Biomarkers in People With Type 2 Diabetes (T2D) and Coronary Heart Disease


CONTRIBUTION TO LITERATURE: The EMPA-HEART trial showed that empagliflozin results in salutary effects on LV remodeling at 6 months among patients with DM2 and stable CAD but normal EF and without a clear history of HF.

DESCRIPTION: The goal of the trial was to assess the efficacy of empagliflozin on left ventricular (LV) remodeling among patients with type 2 diabetes mellitus (DM2) with or without prior heart failure (HF).

STUDY DESIGN: Eligible patients were randomized in a 1:1 fashion to either empagliflozin 10 mg daily (n = 49) or placebo (n = 48).

Read More

Verma S. Presented at AHA 2018.